



Sintilimab for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)


**FDA Opening Remarks
Oncologic Drugs Advisory Committee (ODAC) Meeting
February 10, 2022**

Harpreet Singh, MD
Director, Division of Oncology 2
Office of Oncologic Diseases

Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- Key Review Issues: Generalizability to U.S. Population
- Discussion and Voting Question for ODAC

ORIENT-11: Sintilimab + Chemotherapy for NSCLC Conducted Exclusively in China



Primary endpoints: Progression-free survival (PFS) by independent radiologic review committee (IRRC)

Descriptive secondary endpoints: OS (no α -allocation), overall response rate (ORR), duration of response (DOR)

ORIENT-11 Primary Efficacy Results: PFS by IRRC

	Sintilimab + Chemo N=266	Placebo + Chemo N=131
Events (%)	112 (42)	86 (66)
Median, mos (95% CI) ^a	8.9 (7.1, 11.3)	5.0 (4.8, 6.2)
Hazard ratio (95% CI)^b	0.48 (0.36, 0.64)	
p-value ^c	<0.0001	

Data cut-off (DCO): November 15, 2019

^a Kaplan-Meier estimate

^b Stratified Cox proportional hazard model using Efron's method

^c Two-sided p-value; α bound 0.01958 (interim analysis)

Overall Survival, Overall Response Rate, and Duration of Response were descriptive endpoints not formally tested.



Increasing Number of Single Country Trials

- ORIENT-11 trial design, enrollment criteria, and statistical assumptions closely resemble landmark NSCLC trials which changed treatment paradigm to include immune checkpoint inhibitors
- Reflects at least 25 oncology development programs conducted exclusively in China, many of which closely resemble prior multiregional clinical trials (MRCTs)
- Per ICH E17 guidance, MRCTs preferred approach to globally harmonized drug development

ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- Key Review Issues: Generalizability to U.S. Population
- Discussion and Voting Question for ODAC



CFR 314: Evaluation of Foreign Clinical Data

- An application based solely on foreign clinical data **may** be approved if:
 - **Foreign data applicable to U.S. population and medical practice**
 - Studies performed by investigators of recognized competence
 - FDA validation of data through on-site inspection or other appropriate means

Failure to meet any of these criteria will result in an application not being approvable based on the foreign data alone.

- **FDA will apply this policy in a flexible manner according to nature of drug and data being considered**

Source: 21 CFR 314.106

ICH Guidance: E5 Bridging → E17 MRCT

E5 (1998): sequential bridging from trial in one region to trial in new region




Consider intrinsic and extrinsic factors

Bridging studies fulfilled unmet need.

Inherently limited ability to demonstrate applicability.

Sequential strategy delayed access to important drugs.

E17 (2017): MRCT then evaluate regional consistency




Consider regional variability during planning of MRCT

A 20-year journey from local mindset to global mindset for efficient drug development and to ensure safe and effective drugs worldwide

Asian Countries Participation in MRCTs

Oncology Submissions to the FDA: Patient Enrollment by Geographic Region





ICH E17: Multiregional Clinical Trials (MRCTs)


- Most U.S. drug applications based on international MRCTs
- Allows evaluation of **regional consistency** (i.e., safety and efficacy evaluated across geographic regions and subpopulations)
- Enables **earlier access worldwide** to therapies
- **Avoids duplication** of trials and need for bridging studies
- Promotes **international harmonization** of standard of care practices → facilitates enrollment for future global trials

ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- **Key Review Issues: Generalizability to U.S. Population**
- Discussion and Voting Question for ODAC

KEYNOTE-189: Landmark Approval of Pembrolizumab + Chemotherapy Based on OS



	Pembrolizumab + Chemo N=410	Placebo + Chemo N=206
Events (%)	127 (31)	108 (52)
Median, mos (95% CI)	NR (NR, NR)	11.3 (8.7, 15.1)
Hazard ratio (95% CI)	0.49 (0.38, 0.64)	
p-value	<0.0001	

NR – not reported

Regular approval based on statistically significant improvement in OS

Source: KEYTRUDA (Pembrolizumab) USPI



Control Arm Inapplicable to U.S. Medical Practice

- Enrollment to ORIENT-11 began after FDA approval of pembrolizumab/chemotherapy (KEYNOTE-189) which demonstrated statistically significant OS benefit for patients with nonsquamous NSCLC
- ORIENT-11 could not have been conducted in the United States
 - Lack of investigator support given substandard chemotherapy comparator arm
 - Available FDA approved therapies conferred survival advantage

If consulted, FDA would have likely advised direct comparison of sintilimab to an approved anti-PD-(L)1/chemotherapy regimen with OS endpoint

Study Endpoint Not Applicable to U.S. Regulatory Standards

Drug(s)	Indication*	Approval Endpoint (Year)
Pembrolizumab	NSCLC (TPS \geq 50%)	OS (2016)
Pembrolizumab	NSQ-NSCLC (w/ pemetrexed and platinum chemo)	PFS (2017) ^{AA} ; OS (2018)
Pembrolizumab	SQ-NSCLC (w/ carboplatin and paclitaxel or nab-paclitaxel)	OS (2018)
Atezolizumab	NSQ-NSCLC (w/ carboplatin, paclitaxel, & bevacizumab)	OS and PFS (2018)
Pembrolizumab	NSCLC (TPS \geq 1%)	OS (2019)
Atezolizumab	NSQ-NSCLC (w/ carboplatin & nab-paclitaxel)	OS and PFS (2019)
Nivolumab/Ipilimumab	NSCLC (TPS \geq 1%)	OS (2020)
Nivolumab/Ipilimumab	NSCLC (w/ platinum-doublet chemo)	OS (2020)
Atezolizumab	NSCLC (TC \geq 50% or IC \geq 10%)	OS (2020)
Cemiplimab-rwlc	NSCLC (TPS \geq 50%)	OS (2021)

* Indicated for all NSCLC histologies unless otherwise noted

AA – Accelerated Approval

NSQ – nonsquamous; SQ – squamous



ORIENT-11 not reflective of U.S. population

- Compared to U.S. patients with NSCLC, patients in ORIENT-11 were younger, predominantly male, lower rates of smoking
- Unknown impact of concomitant (herbal) medications
- Unknown impact of differences in body weight/composition
- Fails to address persistent underrepresentation of racial and ethnic minorities in drug development



FDA Validation of Data Limited in Scope

- Few selected clinical sites unable to fully capture heterogeneity in trial conduct and data quality
- Prior participation in MRCTs, as well as previously reported challenges to data integrity are key factors
- ORIENT-11 investigators with limited MRCT experience leading to FDA registration

Woodhead M, *BMJ*, 2016

Applicability to U.S. Population: Applicant Position

1. Similar clinical practice standards between China and U.S.
Standard of care in China at time of trial initiation (2018) not applicable to U.S. patients, who had shifted to first-line immunotherapy
2. Similar pharmacokinetics (PK) and pharmacodynamics (PD) of sintilimab between Chinese and U.S. patients
Insufficient PK data provided to conclude similarity to diverse U.S. population, best evaluated in a MRCT
3. Similar efficacy and safety of sintilimab between Chinese and U.S. patients
Retrospective, exploratory analyses with mixed results, best evaluated in a MRCT




ORIENT-11 Not Applicable to U.S. Population

- **Comparator arm** and **endpoint (PFS)** not consistent with U.S. medical practices and regulatory standards
 - ORIENT-11 lacked FDA consultation and oversight
- **Study population** not reflective of diverse U.S. population
- **Informed consent** not updated to reflect changing standard of care (SOC) as required per good clinical practice (GCP)
- **Inspections limited in scope** to assess trial conduct and data integrity

Therapeutic landscape does not warrant regulatory flexibility.

Applicant's Proposal for Non-Comparative Study Examining Two Doses of Sintilimab



Does not address applicability issues → possible trial would compare sintilimab to approved anti-PD-(L) antibody with OS endpoint

ORIENT-11 Not Envisioned in ICH E5, Not Aligned with ICH E17

- ICH E5 guidance on bridging not intended for “me too” drugs
 - Does not fulfill an unmet regional need
- If designed as a well-conducted MRCT, ORIENT-11 would have:
 - Involved early communication with international regulatory authorities
 - selection of appropriate comparator, OS endpoint
 - Permitted structured exploration of regional consistency of results
 - Addressed concerns about applicability to U.S. population

Building Equity through MRCTs

- MRCTs strengthened by additional regional participants
- Increased diversity may address underrepresentation of ethnic minorities in drug development
- Increased global participation in MRCTs provides a framework to establish regulatory experience
- Patient centered approach expedites therapeutic advances

Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- Key Review Issues: Generalizability to U.S. Population
- Discussion and Voting Question for ODAC



Voting Question

Should additional clinical trial(s) demonstrating applicability to U.S. patients and U.S. medical care be required prior to a final regulatory decision?

Sintilimab for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

**FDA Presentation
Oncologic Drugs Advisory Committee (ODAC) Meeting
February 10, 2022**

Paz J. Vellanki, MD, PhD
Clinical Reviewer, Thoracic and Head and Neck Cancer
Division of Oncology 2, Office of Oncologic Diseases



FDA Review Team

Julia Beaver, M.D., Deputy Director, OOD
Harpreet Singh, M.D., Director, DO2
Martha Donoghue, M.D., Deputy Director, DO2
Erin Larkins, M.D., Supervisory Associate Director, DO2
Nicole Drezner, M.D., Cross-Discipline Team Leader and Clinical Team Leader, DO2
Paz Vellanki, M.D., Ph.D., Clinical Reviewer, DO2
Shenghui Tang, Ph.D., Director, DBV
Yuan-Li Shen, Ph.D., Deputy Director, DBV
Pallavi Mishra-Kalyani, Ph.D., Statistical Team Leader, DBV
Somak Chatterjee, Ph.D., Statistical Reviewer, DBV
Atiqur Rahman, Ph.D., Director, OCP
Jeanne Fourie Zirkelbach, Ph.D., Clinical Pharmacology Team Leader, OCP
Catharine Bulik, Ph.D., Clinical Pharmacology Reviewer, OCP
Jiang Liu, Ph.D., Pharmacometrics Team Leader, DPM
Ye Xing, Ph.D., Pharmacometrics Reviewer, DPM
John Leighton, Ph.D., Director, DHOT
Emily Wearne, Ph.D., Pharmacology Toxicology Team Leader, DHOT
Amy Skinner, Ph.D., Pharmacology Toxicology Reviewer, DHOT
Haoheng Yan, Ph.D., Product Quality Team Leader, OBP
Gunther Boekhoudt, Ph.D., Product Quality Reviewer, OBP
Lee Pai-Scherf, M.D., Site Inspections Reviewer, OSI
Karen Bleich, M.D., Site Inspections Team Leader, OSI
Jana Highsmith, Regulatory Health Project Manager, DRO-ORO
Richard Pazdur, M.D., Director, OCE



Increasing Number of Single Country Trials

- ORIENT-11 trial design, enrollment criteria, and statistical assumptions closely resemble landmark NSCLC trials which changed treatment paradigm to include immune checkpoint inhibitors
- Reflects at least 25 oncology development programs conducted exclusively in China, many of which closely resemble prior multiregional clinical trials (MRCTs)
- Per ICH E17 guidance, MRCTs preferred approach to globally harmonized drug development

ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use



ICH E17: Multiregional Clinical Trials (MRCTs)

- Most U.S. drug applications based on international MRCTs
- Allows evaluation of **regional consistency** (i.e., safety and efficacy evaluated across geographic regions and subpopulations)
- Enables **earlier access worldwide** to therapies
- **Avoids duplication** of trials and need for bridging studies
- Promotes **international harmonization** of standard of care practices → facilitates enrollment for future global trials

ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Outline


- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- Key Review Issues: Generalizability to U.S. Population
- Discussion and Voting Question for ODAC

FDA Mission

The U.S. Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation.

FDA does not consider cost or drug pricing in regulatory decision making.

ORIENT-11: Sintilimab + Chemotherapy for NSCLC Conducted Exclusively in China



Primary endpoints: Progression-free survival (PFS) by independent radiologic review committee (IRRC)


Descriptive secondary endpoints: overall survival (OS; no α -allocation), overall response rate (ORR), duration of response (DOR)

Demographics and Baseline Characteristics

	Sintilimab + Chemo N=266	Placebo + Chemo N=131
Age , median (range)	61 (30 – 75)	61 (35 – 75)
Sex, Male*	204 (77%)	99 (76%)
Race, Chinese (mainland China)	266 (100%)	131 (100%)
ECOG, PS 1	190 (71%)	97 (74%)
Disease Stage		
Stage IIIB/IIIC	21 (8%)	15 (11%)
Stage IV	245 (92%)	116 (89%)
PD-L1*		
<1%	85 (32%)	44 (34%)
≥1%	181 (68%)	87 (66%)
Current/Former Smoker	171 (64%)	87 (66%)
Platinum Choice*		
Cisplatin	71 (27%)	33 (25%)
Carboplatin	195 (73%)	98 (75%)
Brain Metastases	36 (14%)	22 (17%)

* Stratification Factor

Primary Efficacy Results: PFS by IRRC



	Sintilimab + Chemo N=266	Placebo + Chemo N=131
Events (%)	112 (42)	86 (66)
Median, mos (95% CI) ^a	8.9 (7.1, 11.3)	5.0 (4.8, 6.2)
Hazard ratio (95% CI) ^b	0.48 (0.36, 0.64)	
p-value ^c	<0.0001	

Data cut-off (DCO): November 15, 2019

^a Kaplan-Meier estimate

^b Stratified Cox proportional hazard model

^c Two-sided p-value; interim α bound 0.01958

Number of patients at risk

	0	2	4	6	8	10	12	14
Placebo	131	106	77	42	19	4	1	0
Sintilimab	266	231	202	143	63	25	3	3

Overall Survival, Overall Response Rate, and Duration of Response were descriptive endpoints not formally tested.

Summary of Safety

	Sintilimab + Chemo N=266 n (%)	Placebo + Chemo N=131 n (%)
All-cause AEs		
Any Grade	265 (100%)	131 (100%)
Grade 3-4	158 (59%)	69 (53%)
Grade 5	6 (2.3%)	11 (8%)
SAEs	75 (28%)	44 (34%)
AEs Leading to Interruption	125 (47%)	63 (48%)
AEs Leading to Discontinuation	14 (5%)	12 (9%)



ORIENT-11 Not Applicable to U.S. Population

- **Comparator arm** and **endpoint (PFS)** not consistent with U.S. medical practices and regulatory standards
 - ORIENT-11 lacked FDA consultation and oversight
- **Study population** not reflective of diverse U.S. population
- **Informed consent** not updated to reflect changing standard of care (SOC) as required per good clinical practice (GCP)
- **Inspections limited in scope** to assess trial conduct and data integrity


Therapeutic landscape does not warrant regulatory flexibility.



Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- Key Review Issues: Generalizability to U.S. Population
- Discussion and Voting Question for ODAC

Legal Framework and FDA Guidances



ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use



CFR 314: Evaluation of Foreign Clinical Data

- An application based solely on foreign clinical data **may** be approved if:
 - **Foreign data applicable to U.S. population and medical practice**
 - Studies performed by investigators of recognized competence
 - FDA validation of data through on-site inspection or other appropriate means

Failure to meet any of these criteria will result in an application not being approvable based on the foreign data alone.

- **FDA will apply this policy in a flexible manner according to nature of drug and data being considered**

Source: 21 CFR 314.106



Considerations for Regulatory Flexibility

FDA will apply 21 CFR 314.106 in a flexible manner according to nature of drug and data being considered.

- **Unmet medical need**
- **Rare disease:** MRCTs difficult to conduct
- **Novel drug class**

Oncology Drug Development Harmonized by ICH Guidelines



International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) established in 1990



ICH brings together global regulatory authorities and the pharmaceutical industry; China officially joined as a member in 2017



Goal of ICH to harmonize scientific and technical requirements of medicinal products to ensure safe, effective, and high-quality medicines worldwide



ICH guidances used and applied by FDA, and often incorporated into Code of Federal Regulations (CFR)

Source: ich.org

1998 ICH E5 Guidance for Acceptability of Foreign Data

Assessment of data package

- Are clinical trials applicable to **regulatory standards in new region**, including **primary endpoint and control arm**?
- Trials adequate and **well-controlled**?

Sensitivity to ethnic factors

- Extrinsic factors: associated with environment and culture
- Intrinsic factors: define/identify a subpopulation

Need for bridging study

- Based on likelihood that ethnic and extrinsic factors could affect a product's safety or efficacy



ICH – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Ethnic Factors May Impact Drug Efficacy and Safety (ICH E5 and E17)

INTRINSIC		EXTRINSIC
Genetic	Physiological and pathological conditions	Environmental
Gender	Age (children-elderly)	Climate Sunlight Pollution
	Height Bodyweight	Culture Socioeconomic factors Educational status Language
	Liver Kidney Cardiovascular functions	Medical practice Disease definition/Diagnostic Therapeutic approach Drug compliance
	ADME Receptor sensitivity	Smoking Alcohol
Race		Food habits Stress
Genetic polymorphism of the drug metabolism		Regulatory practice/GCP Methodology/Endpoints
Genetic diseases	Diseases	

Source: ICH E5 Guidance – Ethnic Factors in the Acceptability of Foreign Clinical Data

Bridging Studies Inherently Limited

1) Bridging studies may not address concerns regarding generalizability

- Often smaller, non-randomized
- Less clinically meaningful endpoints compared to original trial
- May provide additional pharmacodynamic and clinical data but not sufficient to support a marketing application

2) Reliance on bridging trials resulted in delayed access

Limitations with bridging studies → increased participation in MRCTs

ICH Guidance: E5 Bridging → E17 MRCT

E5 (1998): sequential bridging from trial in one region to trial in new region




Consider intrinsic and extrinsic factors

Bridging studies fulfilled unmet need.

Inherently limited ability to demonstrate applicability.

Sequential strategy delayed access to important drugs.

E17 (2017): MRCT then evaluate regional consistency




Consider regional variability during planning of MRCT


A 20-year journey from local mindset to global mindset for efficient drug development and to ensure safe and effective drugs worldwide

Increased Asian Participation in MRCTs


Oncology Submissions to the FDA: Patient Enrollment by Geographic Region



MRCT Represents Efficient Drug Development



- Earlier access to therapies across different regions
- Avoid duplication of trials and need for bridging studies
- Promote international harmonization



MRCT – multiregional clinical trial

ICH E17 Guiding Principles for MRCTs

1. Strategic use of MRCT's in drug development
2. Intrinsic/extrinsic factors identified early
3. Strategic allocation of sample size to regions
4. Pre-specified pooling of regions or subpopulations
5. **Structured exploration of consistency across regions and subpopulations**
6. Ensure high quality study design and conduct across regions (ICH E6)
7. Communication with regulatory authorities during planning of MRCTs

Inclusion of Diverse Populations in Cancer Drug Development

- Study populations should represent intended populations¹
- Racial and ethnic minorities underrepresented in trials
- Project Equity: FDA Oncology Center of Excellence initiative to promote diversity in clinical trials and generate data in more representative patient groups
- Commitments and initiatives for inclusion and diversity across pharmaceutical industry², professional societies³, and patient advocacy groups⁴

¹ Fashoyin-Aje L, Beaver JA, Pazdur R. *Jama Oncol.* 2021

² Quilici E, www.pharmexec.com, Driving diversity and inclusion, February 2021


³ Clarifyhealth.com, Diversity and inclusion in oncology clinical trials, October 2021

⁴ Kim ES et al., *J Clin Oncol*, October 2017

Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- **Key Review Issues: Generalizability to U.S. Population**
- Discussion and Voting Question for ODAC

KEYNOTE-189: Landmark Approval of Pembrolizumab + Chemotherapy Based on OS




	Pembrolizumab + Chemo N=410	Placebo + Chemo N=206
Events (%)	127 (31)	108 (52)
Median, mos (95% CI)	NR (NR, NR)	11.3 (8.7, 15.1)
Hazard ratio (95% CI)	0.49 (0.38, 0.64)	
p-value	<0.0001	

NR – not reported

Regular approval based on statistically significant improvement in OS

Source: KEYTRUDA (Pembrolizumab) USPI

ORIENT-11 Initiated after Change in U.S. Standard of Care



Control Arm Inapplicable to U.S. Medical Practice

- Enrollment to ORIENT-11 began after FDA approval of pembrolizumab/chemotherapy (KEYNOTE-189) which demonstrated statistically significant OS benefit for patients with nonsquamous NSCLC
- ORIENT-11 could not have been conducted in the United States
 - Lack of investigator support given substandard chemotherapy comparator arm
 - Available FDA approved therapies conferred survival advantage

If consulted, FDA would have likely advised direct comparison of sintilimab to an approved anti-PD-(L)1/chemotherapy regimen with OS endpoint



Precedent of Overall Survival as Approval Endpoint for Immunotherapy Approvals for Metastatic NSCLC

Drug(s)	Indication*	Approval Endpoint (Year)
Pembrolizumab	NSCLC (TPS \geq 50%)	OS (2016)
Pembrolizumab	NSQ-NSCLC (w/ pemetrexed and platinum chemo)	PFS (2017) ^{AA} ; OS (2018)
Pembrolizumab	SQ-NSCLC (w/ carboplatin and paclitaxel or nab-paclitaxel)	OS (2018)
Atezolizumab	NSQ-NSCLC (w/ carboplatin, paclitaxel, & bevacizumab)	OS and PFS (2018)
Pembrolizumab	NSCLC (TPS \geq 1%)	OS (2019)
Atezolizumab	NSQ-NSCLC (w/ carboplatin & nab-paclitaxel)	OS and PFS (2019)
Nivolumab/Ipilimumab	NSCLC (TPS \geq 1%)	OS (2020)
Nivolumab/Ipilimumab	NSCLC (w/ platinum-doublet chemo)	OS (2020)
Atezolizumab	NSCLC (TC \geq 50% or IC \geq 10%)	OS (2020)
Cemiplimab-rwlc	NSCLC (TPS \geq 50%)	OS (2021)

* Indicated for all NSCLC histologies unless otherwise noted

AA – Accelerated Approval

NSQ – nonsquamous; SQ – squamous

ORIENT-11 Endpoint Not Applicable to U.S. Regulatory Standards

- Statistically significant benefit in PFS
- However, OS not statistically tested in ORIENT-11 despite precedent for OS endpoint for approvals in metastatic NSCLC
- For other combination therapies with anti-PD-(L)1 antibodies, OS benefit demonstrated despite crossover in trials → weakens Applicant's position that OS could not have been reasonably tested
- Acceptance of PFS risks loss of gains in OS seen with prior approvals

Applicability to U.S. Population: Applicant Position

1. Similar clinical practice standards between China and U.S.
Standard of care in China at time of trial initiation (2018) not applicable to U.S. patients, who had shifted to first-line immunotherapy
2. Similar pharmacokinetics (PK) and pharmacodynamics (PD) of sintilimab between Chinese and U.S. patients
Insufficient PK data provided to conclude similarity to diverse U.S. Population; best evaluated in a MRCT
3. Similar efficacy and safety of sintilimab between Chinese and U.S. patients
Retrospective, exploratory analyses suggest potential differences; best evaluated in a MRCT

Known Differences Between Patients in U.S. and ORIENT-11

U.S. population with non-squamous NSCLC^{1,2}

- Median age 70 at diagnosis
- ~ 50% male
- ~ 85% current/former smokers
- ~ 79% White
- ~ 15% Black
- ~ 6% Asian

ORIENT-11

- Median age 61
- 76% male
- 65% current/former smokers
- 100% Chinese

¹ Howlader N et al., SEER Cancer Statistics Review, 1975 - 2017

² United States Census Bureau: April 1, 2010 to July 1, 2019

Comparison of Baseline Characteristics

	U.S. Patients with Nonsquamous NSCLC ^{1,2}	KEYNOTE-189 ³ Pembrolizumab N=616	ORIENT-11 ⁴ Sintilimab N=397
Countries of Enrollment, n	N/A	16	1
Race	~ 79% White ~15% Black ~6% Asian	94% White 2.3% Black 2.9% Asian	100% Asian (all Chinese)
Sex, male	~50%	59%	76%
Current/former smokers	~85%	88%	65%
Age, median at diagnosis (range)	~70	64 (34 – 84)	61 (30 – 75)

¹ Howlader N et al., SEER Cancer Statistics Review, 1975 – 2017

² United States Census Bureau: April 1, 2010 to July 1, 2019

³ KEYTRUDA (Pembrolizumab) USPI

⁴ ORIENT-11 Clinical Study Report and Datasets


Unknown Impact of Differences Between Study Population in ORIENT-11 and U.S. Patients

- Diagnosis and management of NSCLC (e.g., decision for chemoradiation)
- Concomitant medications, including herbal medications
 - 69% of patients in ORIENT-11 received at least one herbal medication primarily for adverse events (50%) or prophylactic measures (22%)*
- Body weight and composition
- Unknown regional differences

* Applicant Analysis (data cutoff date: January 15, 2021)

Additional PK Data Needed to Support Dosage, Efficacy, and Safety for U.S. Patients

- Population pharmacokinetic (PopPK) analyses compared pharmacokinetic (PK) characteristics of Chinese (n=475) and U.S. patients (n=39)
- U.S. patients (none with NSCLC): n=30 White, n=5 Black, n=3 Asian, n=1 Native American
- Modeling and simulation data suggest no clinically significant difference in PK between White and Chinese patients, or significant effect of body weight on PK
- **However, limited U.S. patients do not represent ethnic and racial diversity of U.S.**
- FDA standard to request sparse PK collection inclusive of intent-to-treat (ITT) population (i.e., U.S. patient cohort) → **additional PK data needed to support efficacy and safety for U.S. patients**



CN – China; US – United States

Applicant Analysis: Response to Information Request, May 24, 2021



Exploratory Analyses Suggest Differences Between Asian and Non-Asian Patients: Need MRCTs

- Epidemiologic studies suggest Asian ethnicity favorable prognostic factor for OS for NSCLC, in general¹⁻³
- Exploratory studies suggest longer OS with anti-PD-(L)1 antibodies for Asians compared to non-Asians⁴⁻⁷
- Differences in clinicopathological characteristics (smoking history, driver mutations, PD-L1 expression, tumor mutation burden) may contribute to differential survival⁶
- Potential differences in safety, including increased pneumonitis in Asian patients⁷

¹ Ahn MJ, *J Thorac Oncol*, 2010

² Kawaguchi T, *J Thorac Oncol*, 2010

³ Ou SH, *J Thorac Oncol*, 2009

⁴ Peng L, *Oncoimmunology*, 2020

⁵ Chang E et al., ASCO Abstract, 2019

⁶ Qian J. *Int J Cancer*, 2020

⁷ Peng L, *J Thorac Dis*, 2018

Informed Consent Not Updated to Reflect New Approvals with OS Benefit (GCP)

Version	Effective Date	Discussion of Other Treatment Options
1.0	May 11, 2018	Reliance on study doctor to discussion options
2.0	January 29, 2019	Reliance on study doctor to discussion options
March 28, 2019*: Pembrolizumab plus pemetrexed and platinum chemotherapy approved for first-line treatment of nonsquamous NSCLC in China		
3.0	August 13, 2019	Reliance on study doctor to discussion options

***Informed consent form not updated to discuss pembrolizumab approval in China, which demonstrated overall survival benefit**



FDA Site Inspections

(21 CFR 312.68, 312.120, 812.145)

- Requirement for new molecular entities
- Performed to verify accuracy and reliability of clinical trial data
- Not all clinical trial sites inspected → only a sampling of data
- 2016 report by China's State Food and Drug Administration that 80% of clinical trial data from China were "fraudulent or substandard"¹


¹ Woodhead M, *BMJ*, 2016

Uncertain Level of Past Participation of ORIENT-11 Sites in MRCTs

- Prior participation in MRCTs may help provide confidence in trial conduct and data integrity; however, uncertain level of prior participation for ORIENT-11 investigators
- Estimate of prior participation in MRCTs based on participation in trials conducted in both U.S. and China
 - 10 of 48 sites with prior FDA inspections (14 total inspections in Oncology or Hematology)
 - Queried Applicant but unable to indicate 1) number of patients enrolled in MRCTs per site or 2) MRCTs which led to U.S. approval
- Minimal FDA interactions and no prior FDA site inspections for Applicant


Multiple FDA Approved Anti-PD-(L)1 Antibodies with OS Benefit

Pembrolizumab




Source: KEYTRUDA (Pembrolizumab) USPI

Atezolizumab



Source: TECENTRIQ (Atezolizumab) USPI


Nivolumab



Source: OPDIVO (Nivolumab) USPI

- ORIENT-11 does not fulfill unmet need
- Does not merit regulatory flexibility when considering applicability
- Approval based on PFS would diverge from current regulatory standards
- The Applicant compares sintilimab to other first-line therapies, however each must be evaluated on its own merit

Applicant's Proposal for Non-Comparative Study Examining Two Doses of Sintilimab



Does not address applicability issues → possible trial would compare sintilimab to approved anti-PD-(L) antibody with OS endpoint

Proposed Study Does Not Address FDA Concerns

- Dose-finding study rather than study to address concerns of generalizability to U.S. population
- Small study (n=150)
- Less clinically meaningful endpoint (ORR)
- **Proposed study does not address applicability issues → alternatively, a possible trial to address FDA concerns would compare sintilimab to an approved anti-PD-(L)1 antibody with an OS endpoint**

ORIENT-11 Not Envisioned in ICH E5, Not Aligned with ICH E17

- ICH E5 guidance on bridging not intended for “me too” drugs
 - Does not fulfill an unmet regional need
- If designed as a well-conducted MRCT, ORIENT-11 would have:
 - Involved early communication with international regulatory authorities
 - selection of appropriate comparator, OS endpoint
 - Permitted structured exploration of regional consistency of results
 - Addressed concerns about applicability to U.S. population



ORIENT-11 Not Applicable to U.S. Population

- **Comparator arm** and **endpoint (PFS)** not consistent with U.S. medical practices and regulatory standards
 - ORIENT-11 lacked FDA consultation and oversight
- **Study population** not reflective of diverse U.S. population
- **Informed consent** not updated to reflect changing standard of care (SOC) as required per good clinical practice (GCP)
- **Inspections limited in scope** to assess trial conduct and data integrity

Therapeutic landscape does not warrant regulatory flexibility.



Building equity through multiregional clinical trials

Outline

- ORIENT-11 Study Design and Results
- Regulatory Framework for Evaluation of Foreign Data
 - Code of Federal Regulations (CFR)
 - International Council of Harmonisation (ICH) Guidances E5 and E17
- Key Review Issues: Generalizability to U.S. Population
- Discussion and Voting Question for ODAC

Discussion

- Discuss the generalizability of ORIENT-11 to a U.S. population and U.S. medical practice.
- Discuss potential clinical trials (if any) which may address issues of applicability of ORIENT-11 to a U.S. population.



Voting Question

Should additional clinical trial(s) demonstrating applicability to U.S. patients and U.S. medical care be required prior to a final regulatory decision?



BACK-UP SLIDES

FDA Position on Post-hoc OS Analyses

- A formal statistical analysis plan for testing OS was not included for ORIENT-11
 - There was no pre-specified event time for the final analysis of OS
- The applicant has conducted post-hoc analyses assuming various methods for Type I error control for multiple testing of OS at various time points
 - However, this is impossible to do, as to calculate an information fraction (observed events/total number events at final analysis) for these analyses, one must have a pre-specified event-time for the final analysis

Without a detailed, pre-specified analysis plan for statistical testing, these post-hoc results can only be considered hypothesis-generating as there is no scientific rigor to rely upon when considering whether the results are true findings or due to chance.



U.S. FOOD & DRUG
ADMINISTRATION